Treatment for patients with BRAFV600E mutant metastatic colorectal cancer
A Multicenter, Retrospective, Observational Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
This study looks at how well current treatments work for patients in China with advanced colorectal cancer that has a specific BRAFV600E mutation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06749015 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the mutation rate, treatment patterns, effectiveness, and safety of current treatment regimens for patients with BRAFV600E mutant metastatic colorectal cancer (mCRC) in China. It will collect real-world data from multiple centers to better understand the prognosis and survival outcomes for this specific patient population. The study focuses on patients who have been diagnosed with unresectable metastatic colorectal cancer and have confirmed BRAFV600E mutations in their tumor tissue.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with unresectable metastatic colorectal cancer who have a confirmed BRAFV600E mutation.
Not a fit: Patients with previous chronic inflammatory bowel disease, chronic diarrhea, recurrent bowel obstruction, or symptomatic brain metastases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into effective treatment strategies for patients with BRAFV600E mutant mCRC, potentially improving their survival outcomes.
How similar studies have performed: Other studies have shown varying success in understanding treatment patterns for mutant mCRC, but this specific focus on the BRAFV600E mutation in the Chinese population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of histologically or cytologically confirmed CRC that is metastatic and unresectable * Presence of BRAFV600E mutation in tumor tissue, as confirmed by a local assay Exclusion Criteria: * patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction patients with symptomatic brain metastases active clinical severe infection
Where this trial is running
Shanghai, Shanghai Municipality
- Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.